tetano
Editor, Senior Moderator
Gene
. 2022 May 12;146550.
doi: 10.1016/j.gene.2022.146550. Online ahead of print.
Human T-lymphotropic virus type 1 and novel Coronavirus Disease 2019; More complex than just a simple coinfection
Samaneh Sajjadi[SUP] 1 [/SUP], Sepideh Hejazi[SUP] 2 [/SUP], Sahar Ravanshad[SUP] 1 [/SUP], Reza Jafarzadeh Esfehani[SUP] 3 [/SUP]
Affiliations
Abstract
The recent coronavirus disease 2019 (COVID-19) significantly affected many people worldwide, especially those with underlying diseases. While some people with underlying illnesses, including cardiovascular diseases, are more vulnerable to develop severe COVID-19, other populations, including people who have autoimmune diseases, may develop severe diseases similar to the general population. The severity and outcome of COVID-19 are reviewed in individuals with underlying viral diseases, including acquired immune deficiency syndrome and hepatitis, however, some infectious diseases, including human T-lymphotropic virus type 1 (HTLV-1) diseases, is under-reported in the literature. HTLV-1 is a sexually transmitted disease that is endemic in some parts of the world. Infected patients may develop clinical symptoms of HTLV-1 associated myelopathy / tropical spastic paraparesis (HAM/TSP) and adult T cell leukemia (ATL) or may remain asymptomatic during their life. To the best of our knowledge, no clinical studies evaluate the severity and outcomes of SARS-CoV-2 infection in HTLV-1 infected patients. We aimed to review the pathogenesis of both of these viral infections and discuss their similarities in provoking immune responses. Although HTLV-1 infected patients may have had variable degrees of inflammation and immune system dysregulation, the available data is limited to conclude that HTLV-1 infected patients may be more vulnerable to developing severe COVID-19 in contrast to the general population.
Keywords: adult T cell leukemia; coronavirus disease 2019; human T-lymphotropic virus type 1; myelopathy – tropical spastic paraparesis.
. 2022 May 12;146550.
doi: 10.1016/j.gene.2022.146550. Online ahead of print.
Human T-lymphotropic virus type 1 and novel Coronavirus Disease 2019; More complex than just a simple coinfection
Samaneh Sajjadi[SUP] 1 [/SUP], Sepideh Hejazi[SUP] 2 [/SUP], Sahar Ravanshad[SUP] 1 [/SUP], Reza Jafarzadeh Esfehani[SUP] 3 [/SUP]
Affiliations
- PMID: 35569772
- DOI: 10.1016/j.gene.2022.146550
Abstract
The recent coronavirus disease 2019 (COVID-19) significantly affected many people worldwide, especially those with underlying diseases. While some people with underlying illnesses, including cardiovascular diseases, are more vulnerable to develop severe COVID-19, other populations, including people who have autoimmune diseases, may develop severe diseases similar to the general population. The severity and outcome of COVID-19 are reviewed in individuals with underlying viral diseases, including acquired immune deficiency syndrome and hepatitis, however, some infectious diseases, including human T-lymphotropic virus type 1 (HTLV-1) diseases, is under-reported in the literature. HTLV-1 is a sexually transmitted disease that is endemic in some parts of the world. Infected patients may develop clinical symptoms of HTLV-1 associated myelopathy / tropical spastic paraparesis (HAM/TSP) and adult T cell leukemia (ATL) or may remain asymptomatic during their life. To the best of our knowledge, no clinical studies evaluate the severity and outcomes of SARS-CoV-2 infection in HTLV-1 infected patients. We aimed to review the pathogenesis of both of these viral infections and discuss their similarities in provoking immune responses. Although HTLV-1 infected patients may have had variable degrees of inflammation and immune system dysregulation, the available data is limited to conclude that HTLV-1 infected patients may be more vulnerable to developing severe COVID-19 in contrast to the general population.
Keywords: adult T cell leukemia; coronavirus disease 2019; human T-lymphotropic virus type 1; myelopathy – tropical spastic paraparesis.